EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.

ABSTRACT:

Importance

Nivolumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non-small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibitors is still growing, particularly regarding the use of combinations of different classes of antitumor agents, including both the concomitant and sequential use of such agents.

Objective

To determine whether nivolumab increases EGFR-TKI-associated interstitial pneumonitis (IP).

Design, setting, and participants

A database study of 20 516 participants with NSCLC in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, performed between April 2015

SUBMITTER: Oshima Y 

PROVIDER: S-EPMC5885195 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature